Which has stronger valuation and earnings, ENGN or KYNB?

Kyntra Bio has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Kyntra Bio $6.44M 5.38 $183.45M $45.30 0.19

Is ENGN or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to enGene's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Kyntra Bio 2,199.13% N/A -47.27%

Does the media refer more to ENGN or KYNB?

In the previous week, enGene had 11 more articles in the media than Kyntra Bio. MarketBeat recorded 16 mentions for enGene and 5 mentions for Kyntra Bio. enGene's average media sentiment score of 0.00 beat Kyntra Bio's score of 0.00 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CBUS or KYNB?

Kyntra Bio has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $4.35M 27.96 -$127.08M -$1.65 N/A Kyntra Bio $6.44M 5.38 $183.45M $45.30 0.19

Is CBUS or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Cibus' net margin of -2,258.89%. Kyntra Bio's return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Kyntra Bio 2,199.13% N/A -47.27%

Does the media refer more to KYNB or PMN?

In the previous week, Kyntra Bio had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.34 beat Kyntra Bio's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KYNB or ANIX?

In the previous week, Kyntra Bio had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Kyntra Bio and 4 mentions for Anixa Biosciences. Kyntra Bio's average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KYNB or BMEA more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Biomea Fusion's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Biomea Fusion N/A -253.73% -97.91%

Does the media prefer KYNB or BMEA?

In the previous week, Kyntra Bio had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.49 beat Kyntra Bio's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kyntra Bio (KYNB) Competitors

$8.55 +0.06 (+0.71%)

As of 09/4/2026 04:00 PM Eastern

Compare

KYNB vs. ENGN, CBUS, PMN, ANIX, and BMEA

Should you buy Kyntra Bio stock or one of its competitors? Kyntra Bio's main competitors and comparable companies include enGene (ENGN), Cibus (CBUS), Promis Neurosciences (PMN), Anixa Biosciences (ANIX), and Biomea Fusion (BMEA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyntra Bio compare to enGene?

enGene (NASDAQ:ENGN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, enGene had 11 more articles in the media than Kyntra Bio. MarketBeat recorded 16 mentions for enGene and 5 mentions for Kyntra Bio. enGene's average media sentiment score of 0.00 beat Kyntra Bio's score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Kyntra Bio	$6.44M	5.38	$183.45M	$45.30	0.19

enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to enGene's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Kyntra Bio	2,199.13%	N/A	-47.27%

enGene currently has a consensus price target of $11.05, indicating a potential upside of 506.89%. Kyntra Bio has a consensus price target of $36.00, indicating a potential upside of 321.05%. Given enGene's higher probable upside, equities research analysts clearly believe enGene is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

64.2% of enGene shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Kyntra Bio beats enGene on 9 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Cibus?

Cibus (NASDAQ:CBUS) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Kyntra Bio has a net margin of 2,199.13% compared to Cibus' net margin of -2,258.89%. Kyntra Bio's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Kyntra Bio	2,199.13%	N/A	-47.27%

Cibus has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

33.8% of Cibus shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio had 5 more articles in the media than Cibus. MarketBeat recorded 5 mentions for Kyntra Bio and 0 mentions for Cibus. Cibus' average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
Cibus	Neutral
Kyntra Bio	Neutral

Kyntra Bio has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$4.35M	27.96	-$127.08M	-$1.65	N/A
Kyntra Bio	$6.44M	5.38	$183.45M	$45.30	0.19

Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 466.04%. Kyntra Bio has a consensus target price of $36.00, suggesting a potential upside of 321.05%. Given Cibus' higher possible upside, research analysts plainly believe Cibus is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Kyntra Bio beats Cibus on 10 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Promis Neurosciences?

Kyntra Bio (NASDAQ:KYNB) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Kyntra Bio currently has a consensus price target of $36.00, suggesting a potential upside of 321.05%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 169.84%. Given Kyntra Bio's higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Kyntra Bio had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.34 beat Kyntra Bio's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kyntra Bio has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.38	$183.45M	$45.30	0.19
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Promis Neurosciences' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Promis Neurosciences	N/A	-143.09%	-109.15%

Summary

Kyntra Bio beats Promis Neurosciences on 12 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Anixa Biosciences?

Kyntra Bio (NASDAQ:KYNB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kyntra Bio has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.38	$183.45M	$45.30	0.19
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A

Kyntra Bio presently has a consensus target price of $36.00, suggesting a potential upside of 321.05%. Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 176.87%. Given Kyntra Bio's higher probable upside, equities analysts clearly believe Kyntra Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Kyntra Bio has a net margin of 2,199.13% compared to Anixa Biosciences' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Anixa Biosciences	N/A	-71.12%	-62.88%

Kyntra Bio has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

In the previous week, Kyntra Bio had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Kyntra Bio and 4 mentions for Anixa Biosciences. Kyntra Bio's average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kyntra Bio beats Anixa Biosciences on 11 of the 12 factors compared between the two stocks.

How does Kyntra Bio compare to Biomea Fusion?

Kyntra Bio (NASDAQ:KYNB) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Kyntra Bio has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

In the previous week, Kyntra Bio had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.49 beat Kyntra Bio's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio currently has a consensus price target of $36.00, suggesting a potential upside of 321.05%. Biomea Fusion has a consensus price target of $9.00, suggesting a potential upside of 343.35%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kyntra Bio has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.38	$183.45M	$45.30	0.19
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kyntra Bio has a net margin of 2,199.13% compared to Biomea Fusion's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Biomea Fusion	N/A	-253.73%	-97.91%

Summary

Kyntra Bio beats Biomea Fusion on 9 of the 15 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.38M	$4.02B	$7.27B	$12.93B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	0.19	12.71	273.83	25.45
Price / Sales	5.38	1,308.09	608.36	79.33
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	-1.17	16.15	12.85	6.17
Net Income	$183.45M	-$22.80M	$3.49B	$350.08M
7 Day Performance	6.61%	0.31%	1.04%	-0.14%
1 Month Performance	22.32%	8.25%	5.52%	1.02%
1 Year Performance	N/A	49.17%	24.39%	14.51%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	2.4007 of 5 stars	$8.55 +0.7%	$36.00 +321.1%	N/A	$34.38M	$6.44M	0.19	570	Analyst Forecast
ENGN enGene	3.6865 of 5 stars	$1.83 -4.5%	$11.05 +505.2%	-63.6%	$127.94M	N/A	N/A	31	News Coverage
CBUS Cibus	1.8302 of 5 stars	$1.65 -1.2%	$9.00 +445.5%	+26.2%	$127.64M	$3.64M	N/A	48
PMN Promis Neurosciences	2.8998 of 5 stars	$13.78 -1.5%	$34.00 +146.7%	+17.2%	$125.46M	N/A	N/A	5
ANIX Anixa Biosciences	3.7624 of 5 stars	$3.48 -3.3%	$8.50 +144.3%	+3.4%	$122.48M	$210K	N/A	5	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. ENGN, CBUS, PMN, ANIX, and BMEA

How does Kyntra Bio compare to enGene?

Summary

How does Kyntra Bio compare to Cibus?

Summary

How does Kyntra Bio compare to Promis Neurosciences?

Summary

How does Kyntra Bio compare to Anixa Biosciences?

Summary

How does Kyntra Bio compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. ENGN, CBUS, PMN, ANIX, and BMEA

How does Kyntra Bio compare to enGene?

Does the media refer more to ENGN or KYNB?

Which has stronger valuation and earnings, ENGN or KYNB?

Which has more volatility and risk, ENGN or KYNB?

Is ENGN or KYNB more profitable?

Do analysts prefer ENGN or KYNB?

Do insiders & institutionals hold more shares of ENGN or KYNB?

Summary

How does Kyntra Bio compare to Cibus?

Is CBUS or KYNB more profitable?

Which has more volatility & risk, CBUS or KYNB?

Do institutionals and insiders hold more shares of CBUS or KYNB?

Does the media refer more to CBUS or KYNB?

Which has better earnings & valuation, CBUS or KYNB?

Do analysts prefer CBUS or KYNB?

Summary

How does Kyntra Bio compare to Promis Neurosciences?

Do analysts prefer KYNB or PMN?

Does the media refer more to KYNB or PMN?

Do institutionals & insiders hold more shares of KYNB or PMN?

Which has more risk and volatility, KYNB or PMN?

Which has higher valuation & earnings, KYNB or PMN?

Is KYNB or PMN more profitable?

Summary

How does Kyntra Bio compare to Anixa Biosciences?

Do insiders & institutionals hold more shares of KYNB or ANIX?

Which has preferable earnings and valuation, KYNB or ANIX?

Do analysts prefer KYNB or ANIX?

Is KYNB or ANIX more profitable?

Which has more risk & volatility, KYNB or ANIX?

Does the media prefer KYNB or ANIX?

Summary

How does Kyntra Bio compare to Biomea Fusion?

Which has more volatility & risk, KYNB or BMEA?

Does the media prefer KYNB or BMEA?

Do analysts rate KYNB or BMEA?

Which has stronger valuation and earnings, KYNB or BMEA?

Do insiders and institutionals hold more shares of KYNB or BMEA?

Is KYNB or BMEA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools